<DOC>
	<DOCNO>NCT01338558</DOCNO>
	<brief_summary>This randomize , open-label study evaluate safety efficacy Avastin ( Bevacizumab ) add standard mFOLFOX6 chemotherapy treatment-naïve patient Stage IV metastatic colorectal cancer . According K-RAS gene mutation status , patient assign randomized receive either Avastin 5 mg/kg intravenously ( iv ) Day 1 2-week cycle cetuximab 400 mg/m2 iv Day 1 follow 250 mg/m2 iv every week , addition mFOLFOX6 every 2 week . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With mFOLFOX6 Treatment-Naïve Patients With Metastatic Colorectal Cancer With Without K-RAS Mutations , Comparison Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Adult patient &gt; /= 18 year age Histologically confirm adenocarcinoma colon rectum Stage IV metastatic disease least one measurable metastatic lesion accord RECIST criterion Tumour tissue sample available assessment KRAS BRAF gene Prior radiotherapy must complete 4 week randomization Adequate bone marrow , kidney liver function Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Previous chemotherapy metastatic disease Completion adjuvant treatment colorectal cancer ( Stage I , II III ) 12 month precede randomization Prior treatment bevacizumab , cetuximab EGFR inhibitor Clinical radiographic evidence brain metastasis Clinically significant cardiovascular disease disorder History neoplastic disease colorectal cancer 3 year prior start study treatment , except successfully treat noninvasive carcinoma cervical cancer situ , basal cell carcinoma skin superficial bladder tumour HIV , hepatitis B C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>